AFF1 is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain AFF1 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].

ELL is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain ELL status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].

IDH1 is altered in 1.79% of myelofibrosis transformation in essential thrombocythemia patients [2].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH2 is altered in 1.79% of myelofibrosis transformation in essential thrombocythemia patients [2].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 1 is phase 1 (1 open) [3].

JAK2 is altered in 33.93% of myelofibrosis transformation in essential thrombocythemia patients [2].

JAK2 is an inclusion eligibility criterion in 1 clinical trial for myelofibrosis transformation in essential thrombocythemia, of which 1 is open and 0 are closed. Of the trial that contains JAK2 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 1 is phase 2 (1 open) [3].

KMT2A is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain KMT2A status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].

MECOM is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain MECOM status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].

MLLT1 is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain MLLT1 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].

MLLT10 is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain MLLT10 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].

MLLT3 is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain MLLT3 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].

MLLT4 is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain MLLT4 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].

NRIP3 is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain NRIP3 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].

RPN1 is an inclusion eligibility criterion in 16 clinical trials for myelofibrosis transformation in essential thrombocythemia, of which 15 are open and 1 is closed. Of the trials that contain RPN1 status and myelofibrosis transformation in essential thrombocythemia as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (3 open), and 8 are phase 3 (8 open) [3].